These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 18441381)

  • 21. [Role of etravirine in combination antiretroviral therapy].
    Domingo P
    Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():46-51. PubMed ID: 20116628
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Report on the Fifth Conference on Retroviruses and Opportunistic Infections.
    Soloway B
    AIDS Clin Care; 1998 Apr; 10(4):27-9. PubMed ID: 11365150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Raltegravir as antiretroviral therapy in HIV/AIDS.
    Sharma M; Walmsley SL
    Expert Opin Pharmacother; 2014 Feb; 15(3):395-405. PubMed ID: 24304203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Raltegravir: the first HIV integrase inhibitor.
    Cocohoba J; Dong BJ
    Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful integrase inhibitor-based highly active antiretroviral therapy for a multidrug-class-resistant HIV type 1 group O-infected patient in Cameroon.
    Aghokeng AF; Kouanfack C; Peeters M; Mpoudi-Ngole E; Delaporte E
    AIDS Res Hum Retroviruses; 2013 Jan; 29(1):1-3. PubMed ID: 22889147
    [No Abstract]   [Full Text] [Related]  

  • 26. Role of raltegravir in HIV-1 management.
    Rokas KE; Bookstaver PB; Shamroe CL; Sutton SS; Millisor VE; Bryant JE; Weissman SB
    Ann Pharmacother; 2012 Apr; 46(4):578-89. PubMed ID: 22496475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in antiretroviral therapy.
    Sobieszczyk ME; Jones J; Wilkin T; Hammer SM
    Top HIV Med; 2006; 14(1):36-62. PubMed ID: 16641526
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The fusion inhibitor enfuvirtide in recent antiretroviral strategies.
    Makinson A; Reynes J
    Curr Opin HIV AIDS; 2009 Mar; 4(2):150-8. PubMed ID: 19339955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel approaches for the treatment of HIV.
    Arroyo HT
    Newsline People AIDS Coalit N Y; 1998 Mar; ():16-7. PubMed ID: 11367450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Report from Boston: the 12th Conference on Retroviruses and Opportunistic Infections (CROI). New drugs, new targets: good news on the horizon.
    Flexner C
    Hopkins HIV Rep; 2005 Mar; 17(2):8-9. PubMed ID: 16419318
    [No Abstract]   [Full Text] [Related]  

  • 31. Management of human immunodeficiency virus infection in pregnancy.
    Watts DH
    N Engl J Med; 2002 Jun; 346(24):1879-91. PubMed ID: 12063373
    [No Abstract]   [Full Text] [Related]  

  • 32. Advances in antiretroviral therapy.
    Wilkin TJ; Taylor B; Olender S; Hammer SM
    Top HIV Med; 2009; 17(2):68-88. PubMed ID: 19401609
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The drugs we've got...the drugs we're getting...beyond blood. A three-part look at the Fourth Conference on Retroviruses and Opportunistic Infections.
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1997 Apr; 3(4):9-13, 16-8, 21-40. PubMed ID: 11364204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiretroviral therapy and resistance to antiretroviral drugs.
    Lange JM; van Leeuwen R
    Ethiop Med J; 2002 Apr; 40 Suppl 1():51-75. PubMed ID: 12802831
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: a follow-up study.
    Passaes CP; Guimarães ML; Cardoso SW; Pilotto JH; Veloso V; Grinsztejn B; Morgado MG
    J Med Virol; 2012 Dec; 84(12):1869-75. PubMed ID: 23080489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increasing number of anti-HIV drugs but no definite cure. Review of anti-HIV drugs.
    Stolk LM; Lüers JF
    Pharm World Sci; 2004 Jun; 26(3):133-6. PubMed ID: 15230359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sustained HIV RNA suppression after switching from enfuvirtide to etravirine in the early access programme.
    Loutfy M; Ribera E; Florence E; De Wit S; Castagna A; Ryan R; Hill A; Vanaken H; van Delft Y; Marks S
    J Antimicrob Chemother; 2009 Dec; 64(6):1341-4. PubMed ID: 19828488
    [No Abstract]   [Full Text] [Related]  

  • 38. Use of raltegravir in a late presenter HIV-1 woman in advanced gestational age: case report and literature review.
    De Hoffer L; Di Biagio A; Bruzzone B; Sticchi L; Prinapori R; Gerbaldo D; Gotta C; Viscoli C
    J Chemother; 2013 Jun; 25(3):181-3. PubMed ID: 23783144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients.
    Cordery DV; Hesse K; Amin J; Cooper DA
    Antivir Ther; 2010; 15(7):1035-8. PubMed ID: 21041919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
    Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.